Interleukin-15

Leukemia

Essen Biotechprotein_peptidePhase 1/2Active

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 89/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
Vincristine sulfate Inhye Ahn	Phase 3	BB
Cyclophosphamide National Cancer Institute (NCI)	Phase 4	BB
Idarubicin Affiliated Hospital of Nantong University	Phase 3	BB
Daunomycin Richard Stone, MD	Phase 3	BB
Nivestim Hospital General de Mexico	Phase 4	BB

View all 50 →

Same molecule, other indications

Interleukin-15 is also rated in:

acute myeloid leukemiaDormant

B

Indicative · Phase 2

57 / 100

lung carcinomaActive

CCC

Indicative · Phase 1/2

48 / 100

breast cancerActive

CC

Indicative · Phase 1/2

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.